Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions
Background: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, mo...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Institut d'Investigació i Innovació Parc Taulí (I3PT) |
| Repositorio: | r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí |
| OAI Identifier: | oai:dnet:r-i3pt______::ba3f78c9e9f397db708e591d8b4fd0fe |
| Acceso en línea: | https://i3pt.portalinvestigacion.com/publicaciones/6490 https://www.scopus.com/inward/record.uri?eid=2-s2.0-105004307011&doi=10.1016%2Fj.jacig.2025.100474&partnerID=40&md5=5f29e7fe8668b0c9e863f084f894a6b4 |
| Access Level: | acceso abierto |
| Palabra clave: | Dupilumab asthma FENO asthma exacerbation lung function asthma control asthma-related quality of life early response |
| Sumario: | Background: The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab, 300 mg, for an additional 96 weeks (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. Objective: This analysis assessed dupilumab efficacy in patients from QUEST who enrolled in TRAVERSE and were stratified by a reduction in fractional exhaled nitric oxide (FENO) level by week 2 of QUEST. Methods: Patients with an FENO level of at least 25 ppb at parent study baseline (PSBL) were defined as those with or without a minimally important FENO level reduction/response (a >= 20% reduction in patients with an FENO level of >= 50 ppb and a reduction of >10 ppb in those with an FENO level of <50 ppb at PSBL) by week 2 of QUEST. We assessed annualized severe exacerbation rates (AERs) and changes from PSBL in prebronchodilator FEV1 value, 5-item Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score. Results: During QUEST, dupilumab (compared with placebo) reduced AER by 58% to 59% across FENO response subgroups (unadjusted AER 5 0.392-0.523 for dupilumab vs 1.052-1.280 for placebo) and improved prebronchodilator FEV1 value regardless of FENO response. These improvements were sustained during TRAVERSE, with a slightly greater magnitude in FENO responders. Dupilumab also improved 5-item Asthma Control Questionnaire and Asthma Quality of Life Questionnaire scores independently of FENO responses. Conclusion: Dupilumab sustained efficacy for up to 3 years in patients with and without a minimally important early reduction in FENO level. Greater improvements were seen in patients with an early reduction in FENO level, but patients without such a reduction also showed favorable outcomes during their treatment with dupilumab. |
|---|